Get the latest news, insights, and market updates on PYXS (Pyxis Oncology, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
September 2025's Promising Penny Stock Opportunities
As the U.S. stock market experiences fluctuations, with major indices like the Dow Jones and S&P 500 recently hitting record highs before turning lower, investors are closely monitoring economic indicators such as job reports and potential interest rate cuts by the Federal Reserve. In this context, identifying promising investment opportunities becomes crucial. While often considered a relic of past trading days, penny stocks remain relevant for those seeking affordable entry points into... Sep 5, 2025 - $PYXS
Pyxis Oncology to Participate in September Investor and Industry Conferences
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in the following upcoming conferences. Investor Conferences 2025 Cantor Global Healthcare Conference, New York, NY, Wednesday, September 3, 2:45 p.m. ET – Fireside chat and investor one- Aug 21, 2025 - $PYXS
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 – Phase 1/2 combination study of MICVO and KEYTRUDA® (pembrolizumab) progressing well with preliminary data in second half of 2025 – Received a $2.8 million, net of tax, milestone payment from Simcere Pharmaceutical Group Limited for approval of suvemcitug Aug 14, 2025 - $PYXS
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patient May 15, 2025 - $PYXS
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY o May 14, 2025 - $PYXS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple